The Follicle Stimulating Hormone Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Follicle Stimulating Hormone Market:
https://www.thebusinessresearchcompany.com/report/follicle-stimulating-hormone-global-market-report

According to The Business Research Company’s Follicle Stimulating Hormone Global Market Report 2024, The follicle stimulating hormone market size has grown strongly in recent years. It will grow from $1.94 billion in 2023 to $2.05 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%.  The  growth in the historic period can be attributed to increased prevalence of hormonal disorders, growing demand for fertility treatment, expansion of fsh indications, market entry of new fsh products, growing demand for safe and effective contraceptive options.

The follicle stimulating hormone market size is expected to see steady growth in the next few years. It will grow to $2.49 billion in 2028 at a compound annual growth rate (CAGR) of 5.0%.  The growth in the forecast period can be attributed to widening therapeutic applications, rising demand for combination therapy, growing need for effective contraceptive options, aging population and related healthcare needs, market expansion in key regions. Major trends in the forecast period include advanced biosimilar fsh products, regulatory approvals and market access, technological advancements in fsh production and delivery, growing need for effective contraceptive options.

The increasing prevalence of infertility is expected to propel the growth of the follicle-stimulating hormone market. Infertility is a condition affecting the male or female reproductive system that is indicated by the inability to conceive after 12 months or longer of frequent, unprotected sexual contact. Follicle-stimulating hormone encourages the development of eggs in the ovaries and aids in regulating the menstrual cycle in females. It promotes testicular growth in men and aids in producing a protein essential for male fertility by promoting the development of healthy sperm cells. For instance, in April 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, infertility affected around 1 in 6 adults worldwide, or about 17.5% of the adult population. Furthermore, in October 2023, according to the Australian Bureau of Statistics, an Australia-based self-governing constitutional organization entrusted with gathering and analyzing information and making fact-based recommendations to the national, state, and territory governments, there were 300,684 recorded births in 2022, a 3% drop from 2021. The overall fertility rate for all Australian women was 1.63 births per woman. Therefore, the increasing prevalence of infertility is driving the growth of the follicle-stimulating hormone market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12486&type=smp

The follicle stimulating hormone market covered in this report is segmented –

1) By Type: Recombinant FSH, Urinary FSH

2) By Application: Infertility Treatment, Assisted Reproductive Technology (ART), Other Applications

3) By End-Users: Infertility Center, Hospitals, Other End-Users

Top Major Players:
Pfizer Inc.
Novartis AG
Abbott Laboratories
Sanofi S.A
Boehringer Ingelheim GmbH

North America was the largest region in the follicle stimulating hormone market in 2023.

Product innovations are a key trend gaining popularity in the follicle-stimulating hormone market. Major companies operating in the follicle-stimulating hormone market are focused on developing innovative products to strengthen their position in the market. For instance, in August 2021, Merck Specialties Pvt. Ltd., an India-based healthcare company, introduced the Pergoveris Pen, aiming to enhance infertility treatment options in the country. The Pergoveris Pen is an innovative device that combines recombinant follicle-stimulating hormone (FSH) and recombinant luteinizing hormone (LH) in a convenient, pre-filled format. It is the first to combine these hormones within a pen injector. Designed for prescribed use by IVF specialists, the Pergoveris Pen offers a combination treatment solution specifically for women experiencing severe deficiencies in follicle stimulating hormone (FSH) and luteinizing hormone (LH).

The follicle stimulating hormone market report table of contents includes:

1. Executive Summary
2. Follicle Stimulating Hormone Market Characteristics
3. Follicle Stimulating Hormone Market Trends And Strategies
4. Follicle Stimulating Hormone Market - Macro Economic Scenario
5. Global Follicle Stimulating Hormone Market Size and Growth
…
32. Global Follicle Stimulating Hormone Market Competitive Benchmarking
33. Global Follicle Stimulating Hormone Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Follicle Stimulating Hormone Market
35.Follicle Stimulating Hormone Market Future Outlook and Potential Analysis
36. Appendix

Contact Us: 
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model